Skip to content
Strensiq(asfotase alfa)
Strensiq (asfotase alfa) is an enzyme pharmaceutical. Asfotase alfa was first approved as Strensiq on 2015-08-28. It is used to treat hypophosphatasia in the USA. It has been approved in Europe to treat hypophosphatasia.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Strensiq
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Asfotase alfa
Tradename
Proper name
Company
Number
Date
Products
Strensiqasfotase alfaAlexion PharmaceuticalsN-125513 RX2015-10-23
4 products
Labels
FDA
EMA
Brand Name
Status
Last Update
strensiqBiologic Licensing Application2020-06-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypophosphatasia—D007014E83.39
Agency Specific
FDA
EMA
Expiration
Code
asfotase alfa, Strensiq, Alexion Pharmaceuticals, Inc.
2122-10-23Orphan excl.
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A16: Other alimentary tract and metabolism products in atc
— A16A: Other alimentary tract and metabolism products in atc
— A16AB: Enzymes for alimentary tract and metabolism
— A16AB13: Asfotase alfa
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypophosphatasiaD007014E83.392912315
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameASFOTASE ALFA
INNasfotase alfa
Description
Asfotase alfa, sold under the brand name Strensiq, is a medication used in the treatment of people with perinatal/infantile- and juvenile-onset hypophosphatasia.
Classification
Enzyme
Drug classenzymes
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2108311
ChEBI ID—
PubChem CID—
DrugBankDB09105
UNII IDZ633861EIM (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Strensiq - Alexion Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Strensiq - AstraZeneca
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 294 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
8,134 adverse events reported
View more details